126 related articles for article (PubMed ID: 37913735)
1. SHP2 potentiates anti-PD-1 effectiveness through intervening cell pyroptosis resistance in triple-negative breast cancer.
Chen C; Cheng Y; Lei H; Feng X; Zhang H; Qi L; Wan J; Xu H; Zhao X; Zhang Y; Yang B
Biomed Pharmacother; 2023 Dec; 168():115797. PubMed ID: 37913735
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin Induces Pyroptosis via Activation of MEG3/NLRP3/caspase-1/GSDMD Pathway in Triple-Negative Breast Cancer.
Yan H; Luo B; Wu X; Guan F; Yu X; Zhao L; Ke X; Wu J; Yuan J
Int J Biol Sci; 2021; 17(10):2606-2621. PubMed ID: 34326697
[TBL] [Abstract][Full Text] [Related]
3. SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer.
Martin E; Agazie YM
Mol Cancer Res; 2021 Nov; 19(11):1946-1956. PubMed ID: 34389690
[TBL] [Abstract][Full Text] [Related]
4. Nigericin Boosts Anti-Tumor Immune Response via Inducing Pyroptosis in Triple-Negative Breast Cancer.
Wu L; Bai S; Huang J; Cui G; Li Q; Wang J; Du X; Fu W; Li C; Wei W; Lin H; Luo ML
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370831
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
[TBL] [Abstract][Full Text] [Related]
6. PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.
Amante RJ; Jehanno C; De Silva D; Coissieux MM; Ackerknecht M; Romanet V; Sethi A; Hamelin B; Preca BT; Piscuoglio S; Ng CKY; Mohseni M; Bentires-Alj M
J Mammary Gland Biol Neoplasia; 2023 Jun; 28(1):13. PubMed ID: 37294349
[TBL] [Abstract][Full Text] [Related]
7. Silencing MFHAS1 Induces Pyroptosis
Jin Y; Zhai M; Cao R; Yu H; Wu C; Liu Y
Curr Pharm Des; 2023; 29(42):3408-3420. PubMed ID: 37936452
[TBL] [Abstract][Full Text] [Related]
8. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells.
Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810
[TBL] [Abstract][Full Text] [Related]
9. Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway.
Yang Y; Liu PY; Bao W; Chen SJ; Wu FS; Zhu PY
BMC Cancer; 2020 Jan; 20(1):28. PubMed ID: 31924176
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment.
Zhao H; Agazie YM
BMC Cancer; 2015 Mar; 15():109. PubMed ID: 25885600
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis.
Xu W; Song C; Wang X; Li Y; Bai X; Liang X; Wu J; Liu J
Aging (Albany NY); 2021 Jan; 13(1):228-240. PubMed ID: 33472170
[TBL] [Abstract][Full Text] [Related]
13. Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer.
Chen H; Cresswell GM; Libring S; Ayers MG; Miao J; Zhang ZY; Solorio L; Ratliff TL; Wendt MK
Cancer Res Commun; 2022 Oct; 2(10):1104-1118. PubMed ID: 36969745
[TBL] [Abstract][Full Text] [Related]
14. The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy.
Wang X; Li H; Li W; Xie J; Wang F; Peng X; Song Y; Tan G
Cell Biol Toxicol; 2020 Oct; 36(5):437-457. PubMed ID: 31993881
[TBL] [Abstract][Full Text] [Related]
15. β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis.
Wu Z; Wu H; Wang Z; Li H; Gu H; Xia E; Yan C; Dai Y; Liu C; Wang X; Lv L; Bao J; Wang O; Dai X
Phytomedicine; 2023 Jun; 114():154769. PubMed ID: 36940580
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.
Chen X; Shu C; Li W; Hou Q; Luo G; Yang K; Wu X
J Med Chem; 2022 May; 65(9):6729-6747. PubMed ID: 35447031
[TBL] [Abstract][Full Text] [Related]
17. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
[No Abstract] [Full Text] [Related]
18. Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor.
Li J; Kang Y; Wei L; Liu W; Tian Y; Chen B; Lin X; Li Y; Feng GS; Lu Z
PLoS One; 2014; 9(7):e102847. PubMed ID: 25048202
[TBL] [Abstract][Full Text] [Related]
19. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.
Sausgruber N; Coissieux MM; Britschgi A; Wyckoff J; Aceto N; Leroy C; Stadler MB; Voshol H; Bonenfant D; Bentires-Alj M
Oncogene; 2015 Apr; 34(17):2272-8. PubMed ID: 24931162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
